Isabella Testa

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.

Journal: European urology
Published: February 03, 2026

A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer.

A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer.

Journal: European urology oncology
Published: June 13, 2025

Reply to: Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.

Reply to: Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 17, 2025

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 16, 2024

Safety profile and treatment response of everolimus in different solid tumors: an observational study.

Safety profile and treatment response of everolimus in different solid tumors: an observational study.

Journal: Future oncology (London, England)
Published: August 23, 2014

Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor.

Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor.

Journal: Future oncology (London, England)
Published: July 24, 2014

Response to targeted therapy in urachal adenocarcinoma.

Response to targeted therapy in urachal adenocarcinoma.

Journal: Rare tumors
Published: June 25, 2014

Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data.

Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data.

Journal: Clinical genitourinary cancer
Published: June 18, 2014

Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients.

Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients.

Journal: Oncology
Published: May 25, 2014

Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.

Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.

Journal: Anticancer research
Published: April 30, 2014

Targeted treatments in advanced renal cell carcinoma: focus on axitinib.

Targeted treatments in advanced renal cell carcinoma: focus on axitinib.

Journal: Pharmacogenomics and personalized medicine
Published: April 10, 2014

Everolimus in advanced solid tumors: when to start, early or late?

Everolimus in advanced solid tumors: when to start, early or late?

Journal: Tumori
Published: March 29, 2014
Showing 1-12 of 20

Last Updated: 09/26/2026